Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | MGMT | P16455 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10157914 | 1.00 | HTR2A (0.38) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL10157888 | 0.85 | HTR2A (0.38) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL10157929 | 0.85 | HTR2A (0.38) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL10157878 | 0.82 | LMNA (0.42) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL10157714 | 0.82 | LMNA (0.42) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL15829114 | 0.82 | LMNA (0.42) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL10157881 | 0.81 | HTR2A (0.38) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL15829111 | 0.81 | HTR2A (0.38) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL10157912 | 0.81 | HTR2A (0.38) | HTR2AHTR2CLMNAALDH1A1HTT | |
| SCHEMBL17692676 | 0.80 | HTR2A (0.36) | HTR2AHTR2CLMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907104-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140179929-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-26 | — | — | US | disclosed |
| US-8580969-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130217886-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-22 | — | — | US | disclosed |
| US-8293920-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120029199-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-7960559-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | MYERS ANDREW G | 2011-01-13 | — | — | US | disclosed |
| US-7763735-B2 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217886-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | HTR2A 4737/4885HTR2C 4653/4885LMNA 1039/4885 |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | HTR2A 4737/4885HTR2C 4653/4885LMNA 1039/4885 |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | TECR, TSN, TARS2 | HTR2A 4687/4885HTR2C 4665/4885LMNA 1906/4885 |
| US-20140179929-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | HTR2A 4737/4885HTR2C 4653/4885LMNA 1039/4885 |
| US-20120029199-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | HTR2A 4737/4885HTR2C 4653/4885LMNA 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.